Filter
Associated Lab
- Betzig Lab (2) Apply Betzig Lab filter
- Dickson Lab (2) Apply Dickson Lab filter
- Gonen Lab (1) Apply Gonen Lab filter
- Grigorieff Lab (1) Apply Grigorieff Lab filter
- Keller Lab (2) Apply Keller Lab filter
- Koay Lab (1) Apply Koay Lab filter
- Looger Lab (2) Apply Looger Lab filter
- Otopalik Lab (1) Apply Otopalik Lab filter
- Pavlopoulos Lab (1) Apply Pavlopoulos Lab filter
- Pedram Lab (1) Apply Pedram Lab filter
- Singer Lab (2) Apply Singer Lab filter
- Stern Lab (1) Apply Stern Lab filter
- Sternson Lab (1) Apply Sternson Lab filter
- Svoboda Lab (2) Apply Svoboda Lab filter
- Truman Lab (1) Apply Truman Lab filter
- Wang (Shaohe) Lab (1) Apply Wang (Shaohe) Lab filter
Associated Project Team
Publication Date
- March 29, 2019 (1) Apply March 29, 2019 filter
- March 27, 2019 (1) Apply March 27, 2019 filter
- March 26, 2019 (1) Apply March 26, 2019 filter
- March 25, 2019 (2) Apply March 25, 2019 filter
- March 22, 2019 (1) Apply March 22, 2019 filter
- March 21, 2019 (1) Apply March 21, 2019 filter
- March 19, 2019 (3) Apply March 19, 2019 filter
- March 16, 2019 (1) Apply March 16, 2019 filter
- March 14, 2019 (1) Apply March 14, 2019 filter
- March 12, 2019 (2) Apply March 12, 2019 filter
- March 8, 2019 (3) Apply March 8, 2019 filter
- March 7, 2019 (2) Apply March 7, 2019 filter
- March 6, 2019 (1) Apply March 6, 2019 filter
- March 1, 2019 (1) Apply March 1, 2019 filter
- Remove March 2019 filter March 2019
Type of Publication
21 Publications
Showing 21-21 of 21 resultsChemogenetics enables non-invasive chemical control over cell populations in behaving animals. However, existing small molecule agonists show insufficient potency or selectivity. There is also need for chemogenetic systems compatible with both research and human therapeutic applications. We developed a new ion channel-based platform for cell activation and silencing that is controlled by low doses of the anti-smoking drug varenicline. We then synthesized novel sub-nanomolar potency agonists, called uPSEMs, with high selectivity for the chemogenetic receptors. uPSEMs and their receptors were characterized in brains of mice and a rhesus monkey by in vivo electrophysiology, calcium imaging, positron emission tomography, behavioral efficacy testing, and receptor counterscreening. This platform of receptors and selective ultrapotent agonists enables potential research and clinical applications of chemogenetics.